Point Of Care Diagnostic MarketSize, Share & Industry Analysis, 2026-2034By TechnologyBy ProductBy End-useBy Sample TypeBy Distribution Channel
Full title & scope — all 5 axes with their segments
Point Of Care Diagnostic Market Size, Share & Industry Analysis, By Technology (Lateral Flow Assays, Immunoassay-based Platforms, Biosensor-based Platforms, Molecular/PCR-based POC, Microfluidics-based Platforms), By Product (Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Infectious Disease, HIV POC, Clostridium Difficile POC, HBV POC, Pneumonia or Streptococcus Associated Infections, HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB and Drug-resistant TB POC, HSV POC, COVID-19, Other Infectious Diseases, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug of Abuse (DOA) Testing, Urinalysis/Nephrology), By End-use (Hospitals, Home, Physician Office, Clinics, Laboratory, Pharmacy & Retail Clinics, Urgent Care Clinics, Non-practice Clinics, Assisted Living Healthcare Facilities), By Sample Type (Blood/Serum/Plasma, Urine, Nasal/Nasopharyngeal Swab, Saliva, Other), By Distribution Channel (Direct/Institutional Tender, Retail Pharmacy, Online/Direct-to-Consumer), and Regional Forecast, 2026-2034
Segment definitions and share of revenue by product, animal, end user and region.
- 01By TechnologyLateral Flow Assays · Immunoassay-based Platforms · Biosensor-based Platforms
- 02By ProductGlucose Testing · Hb1Ac Testing · Coagulation Testing
- 03By End-useHospitals · Home · Physician Office
- 04By Sample TypeBlood/Serum/Plasma · Urine · Nasal/Nasopharyngeal Swab
- 05By Distribution ChannelDirect/Institutional Tender · Retail Pharmacy · Online/Direct-to-Consumer
- 06By Region
Market Analysis & Outlook
Point-of-care diagnostics are testing devices and assay systems designed to deliver a result at or near the site of patient care, rather than requiring a sample to be sent to a central laboratory. The category spans handheld meters, cartridge-based analyzers, lateral flow strips and benchtop instruments used to measure analytes such as glucose, infectious disease markers, cardiac and coagulation parameters, and hormones. Buyers include hospitals, physician offices, retail and urgent care clinics, public health programs and increasingly patients themselves testing at home.
Growth of 8.21% a year carries the global point of care diagnostic market from USD 28.5 billion in 2025 to USD 56.74 billion in 2034. The full series behind that rate covers USD 24.1 billion in 2020, USD 27.8 billion in 2024, USD 30.2 billion in 2026 and USD 41.4 billion in 2030, with 2025 as the base year.
On the technology axis, growth rates run from 5.88% for Lateral Flow Assays up to 11.62% for Molecular/PCR-based POC. Lateral Flow Assays carries the volume: USD 9.69 billion and 34% of revenue in 2025, USD 15.89 billion and 28% in 2034. Share moves toward Biosensor-based Platforms, Molecular/PCR-based POC and Microfluidics-based Platforms and away from Lateral Flow Assays and Immunoassay-based Platforms, though no line shrinks in revenue terms.
By product, Glucose Testing accounts for 18.81% of 2025 revenue at USD 5.36 billion, reaching USD 9.65 billion and 17.01% by 2034. HPV POC grows faster at 14.2% against 6.75%, moving from 1.51% of revenue to 2.5% by 2034. This axis divides the same revenue as the technology split instead of adding to it, so the two are read together and never summed.
North America is the largest region at 38% of 2025 revenue, worth USD 10.83 billion and reaching USD 19.29 billion by 2034. Asia Pacific follows at 26%, moving from USD 7.41 billion to USD 18.17 billion, and Middle East and Africa is the smallest at 6%. Asia Pacific gain share across the period, so growth is not distributed evenly between regions.
The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five technology lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 8.21% takes the market from USD 28.5 billion in 2025 to USD 56.74 billion in 2034, against 3.41% recorded over the 2020-2025 historical period.
- 34% of 2025 revenue sits in Lateral Flow Assays (USD 9.69 billion) and it remains the largest technology line in 2034 at USD 15.89 billion and 28%.
- Molecular/PCR-based POC is the fastest-growing line at 11.62%, lifting its share from 15% in 2025 to 20% in 2034 and its revenue from USD 4.28 billion to USD 11.35 billion.
- The bull case puts 2034 revenue at USD 64.12 billion and the bear case at USD 49.65 billion, either side of the USD 56.74 billion base case, each with its own stated assumption in the full report.
- 38% of 2025 revenue is generated in North America, worth USD 10.83 billion and rising to USD 19.29 billion by 2034; Middle East and Africa is smallest at 6%.
- 85% of North America's base-year revenue comes from the United States alone: USD 9.21 billion in 2025, rising to USD 16.4 billion by 2034, which is why it is that region's worked example.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By by technology
Base year 2025Lateral Flow Assays leads with 34.0% of by technology segment revenue.
Share of by technology segment revenue, most recent base year.
The global point of care diagnostic market is shaped over 2026-2034 by three measurable movements: a change in the technology mix, a shift in where revenue sits geographically, and the 8.21% rate carrying the total.
The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.
Composition shifts on the technology axis. 11.62% against 5.88%: that gap, between Molecular/PCR-based POC and Lateral Flow Assays, is the largest on the technology axis. Shares follow: 15% to 20% for Molecular/PCR-based POC, 34% to 28% for Lateral Flow Assays. Revenue rises on both sides; USD 4.28 billion to USD 11.35 billion and USD 9.69 billion to USD 15.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Regional weight shifts toward Asia Pacific. Asia Pacific moves from 26% of revenue in 2025 to 32% in 2034, worth USD 7.41 billion rising to USD 18.17 billion. Share moves off the others in turn: North America at 38% moving to 34%, Europe at 24% moving to 22%, Latin America at 6% moving to 6%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.
The series never breaks trajectory. Fifteen years of revenue run USD 24.1 billion in 2020, USD 27.8 billion in 2024, USD 28.5 billion in 2025, USD 30.2 billion in 2026, USD 41.4 billion in 2030 and USD 56.74 billion in 2034. The forecast rate of 8.21% sits against 3.41% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the technology and regional axes, not by the headline rate.
Market Growth Factors
Growth is concentrated in Molecular/PCR-based POC
Market Drivers
3- 01Growth is concentrated in Molecular/PCR-based POC
Molecular/PCR-based POC compounds at 11.62% against 8.21% for the market, rising from USD 4.28 billion in 2025 to USD 11.35 billion in 2034 and from 15% of revenue to 20%. The market's overall 8.21% depends on that rate holding: at the 5.88% recorded by Lateral Flow Assays, the same revenue base would compound to a materially smaller 2034 total. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Regional weight, not regional count
North America is the largest region at USD 10.83 billion in 2025, 38% of global revenue, and reaches USD 19.29 billion by 2034 while holding 34%. Asia Pacific is next at 26% of revenue, USD 7.41 billion in 2025 and USD 18.17 billion in 2034. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03A demonstrated trajectory, not a projected turnaround
The historical period compounded at 3.41%; USD 24.1 billion in 2020, USD 27.8 billion in 2024 and USD 28.5 billion in 2025. The forecast continues at 8.21% to USD 56.74 billion in 2034. Because the growth is already in the record and not only in the projection, the rate is held flat across the forecast instead of ramped, and the risk in the number sits in the mix assumptions, not in whether the market grows at all.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising chronic disease burden driving decentralized glucose and cardiometabolic monitoring | High | +9.5 | High | High | High |
| 2 | Expansion of infectious disease testing access in outpatient and home settings | High | +6.8 | High | Medium | Medium |
| 3 | Growth in home-based and self-testing adoption supported by telehealth integration | Medium-High | +5.6 | Medium | High | High |
| 4 | Regulatory support for CLIA-waived and point-of-care test approvals | Medium | +3.9 | Medium | Medium | Medium |
| 5 | Investment in molecular and biosensor-based point-of-care platforms | Medium | +3.2 | Low | Medium | High |
| 6 | Others | Low | +1.5 | Low | Low | Low |
| Total | +30.5 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Reimbursement constraints and payer scrutiny on point-of-care test pricing | Medium | −1.4 | Medium | Medium | Medium |
| 2 | Quality and accuracy concerns limiting adoption of certain rapid assays | Medium | −0.86 | Medium | Low | Low |
| Total | −2.26 | |||||
Drivers contribute 30.5 Billion and restraints remove 2.26 Billion, a net 28.24 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Three sources account for the growth to 2034: 8.21% compounding across the base, share moving toward the faster technology lines, and above-market expansion in the leading regions.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
The bear case assumes reimbursement tightening for point-of-care testing and a slower shift of infectious disease and chronic disease testing away from central laboratories than currently observed. On that assumption 2034 revenue lands at USD 49.65 billion against the USD 56.74 billion base case, from the same USD 28.5 billion 2025 starting point.
- 02Lateral Flow Assays grows below the market rate
Lateral Flow Assays carries 34% of 2025 revenue at USD 9.69 billion but compounds at 5.88% against 8.21% for the market, taking its share to 28% by 2034 even as revenue rises to USD 15.89 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 64.12 billion by 2034
Market Opportunities
2- 01Upside case: USD 64.12 billion by 2034
What would beat the forecast: the bull case assumes faster clearance and reimbursement of molecular and biosensor point-of-care platforms alongside sustained expansion of home and retail testing access. That case reaches USD 64.12 billion in 2034 against USD 56.74 billion, and it is worth testing against a reader's own read of the market.
- 02Molecular/PCR-based POC share moves from 15% to 20%
Molecular/PCR-based POC grows at 11.62% against 8.21% for the market, adding revenue from USD 4.28 billion in 2025 to USD 11.35 billion in 2034 and taking its share from 15% to 20%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Lateral Flow Assays.
Market Challenges
Concentration on the technology axis
Market Challenges
2- 01Concentration on the technology axis
USD 9.69 billion of 2025 revenue sits in Lateral Flow Assays, 34% of the total, and it is still 28% at USD 15.89 billion nine years later. That concentration means the market's own forecast is, to a large extent, a forecast for one technology line.
- 02One country drives the leading region
85% of the leading region is one country: the United States, at USD 9.21 billion against North America's USD 10.83 billion in 2025, and USD 16.4 billion by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesThe market is divided by technology and by product, end-use, sample type and distribution channel; five axes in all. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.
Five technology lines are reported. Three of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Technology · 5 segments
Lateral Flow Assays Led by Technology in 2025, with Molecular/PCR-based POC Growing Fastest
- Largest Lateral Flow Assays · 34%
- Fastest Molecular/PCR-based POC · 11.6%
- Moves most Lateral Flow Assays · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Lateral Flow Assays | $9.69B | 34% | $15.89B | 28%-6 | 5.9% |
| Immunoassay-based Platforms | $7.41B | 26% | $13.62B | 24%-2 | 7.2% |
| Biosensor-based Platforms | $4.56B | 16% | $10.21B | 18%+2 | 9.6% |
| Molecular/PCR-based POC | $4.28B | 15% | $11.35B | 20%+5 | 11.6% |
| Microfluidics-based Platforms | $2.56B | 9% | $5.67B | 10%+1 | 9.5% |
Lateral flow assays lead because they require no instrumentation, tolerate a wide range of sample types, and remain the default choice for infectious disease and pregnancy screening in decentralized settings. Molecular and PCR-based platforms are growing fastest as miniaturized cartridge systems bring laboratory-grade sensitivity to urgent care and outpatient settings, supporting confirmatory testing for resistant and emerging pathogens. The order does not change: Lateral Flow Assays is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Product · 27 segments
By Product
- Largest Glucose Testing · 18.8%
- Fastest HPV POC · 14.2%
- Moves most COVID-19 · -4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Glucose Testing | $5.36B | 18.8% | $9.65B | 17%-1.8 | 6.8% |
| Hb1Ac Testing | $1.14B | 4% | $2.27B | 4% | 8% |
| Coagulation Testing | $1.14B | 4% | $2.27B | 4% | 8% |
| Fertility/Pregnancy | $1.71B | 6% | $3.12B | 5.5%-0.5 | 6.9% |
| Infectious Disease | $1.43B | 5% | $2.84B | 5% | 7.9% |
| HIV POC | $1.14B | 4% | $2.27B | 4% | 8% |
| Clostridium Difficile POC | $0.43B | 1.5% | $0.85B | 1.5% | 7.9% |
| HBV POC | $0.57B | 2% | $1.13B | 2% | 7.9% |
| Pneumonia or Streptococcus Associated Infections | $0.86B | 3% | $1.99B | 3.5%+0.5 | 9.8% |
| HPV POC | $0.43B | 1.5% | $1.42B | 2.5%+1 | 14.2% |
| Influenza/Flu POC | $1.14B | 4% | $2.27B | 4% | 8% |
| HCV POC | $0.57B | 2% | $1.13B | 2% | 7.9% |
| MRSA POC | $0.43B | 1.5% | $0.85B | 1.5% | 7.9% |
| TB and Drug-resistant TB POC | $0.71B | 2.5% | $1.70B | 3%+0.5 | 10.2% |
| HSV POC | $0.29B | 1% | $0.57B | 1% | 7.8% |
| COVID-19 | $1.71B | 6% | $1.13B | 2%-4 | -4.5% |
| Other Infectious Diseases | $0.86B | 3% | $1.99B | 3.5%+0.5 | 9.8% |
| Thyroid Stimulating Hormone | $0.71B | 2.5% | $1.42B | 2.5% | 8% |
| Hematology | $1.14B | 4% | $2.55B | 4.5%+0.5 | 9.4% |
| Primary Care Systems | $0.86B | 3% | $1.99B | 3.5%+0.5 | 9.8% |
| Feces | $0.43B | 1.5% | $0.85B | 1.5% | 7.9% |
| Lipid Testing | $0.86B | 3% | $1.70B | 3% | 7.9% |
| Cancer Marker | $0.86B | 3% | $2.55B | 4.5%+1.5 | 12.8% |
| Blood Gas/Electrolytes | $1.14B | 4% | $2.55B | 4.5%+0.5 | 9.4% |
| Ambulatory Chemistry | $0.86B | 3% | $1.99B | 3.5%+0.5 | 9.8% |
| Drug of Abuse (DOA) Testing | $0.86B | 3% | $1.70B | 3% | 7.9% |
| Urinalysis/Nephrology | $0.86B | 3% | $1.99B | 3.5%+0.5 | 9.8% |
2025 to 2034 revenue and share by line: Glucose Testing USD 5.36 billion to USD 9.65 billion (18.81% in 2025), Fertility/Pregnancy USD 1.71 billion to USD 3.12 billion (6% in 2025), COVID-19 USD 1.71 billion to USD 1.13 billion (6% in 2025), Infectious Disease USD 1.43 billion to USD 2.84 billion (5.02% in 2025), Hb1Ac Testing USD 1.14 billion to USD 2.27 billion (4% in 2025), Coagulation Testing USD 1.14 billion to USD 2.27 billion (4% in 2025), HIV POC USD 1.14 billion to USD 2.27 billion (4% in 2025), Influenza/Flu POC USD 1.14 billion to USD 2.27 billion (4% in 2025), Hematology USD 1.14 billion to USD 2.55 billion (4% in 2025), Blood Gas/Electrolytes USD 1.14 billion to USD 2.55 billion (4% in 2025), Pneumonia or Streptococcus Associated Infections USD 0.86 billion to USD 1.99 billion (3.02% in 2025), Other Infectious Diseases USD 0.86 billion to USD 1.99 billion (3.02% in 2025), Primary Care Systems USD 0.86 billion to USD 1.99 billion (3.02% in 2025), Lipid Testing USD 0.86 billion to USD 1.7 billion (3.02% in 2025), Cancer Marker USD 0.86 billion to USD 2.55 billion (3.02% in 2025), Ambulatory Chemistry USD 0.86 billion to USD 1.99 billion (3.02% in 2025), Drug of Abuse (DOA) Testing USD 0.86 billion to USD 1.7 billion (3.02% in 2025), Urinalysis/Nephrology USD 0.86 billion to USD 1.99 billion (3.02% in 2025), TB and Drug-resistant TB POC USD 0.71 billion to USD 1.7 billion (2.49% in 2025), Thyroid Stimulating Hormone USD 0.71 billion to USD 1.42 billion (2.49% in 2025), HBV POC USD 0.57 billion to USD 1.13 billion (2% in 2025), HCV POC USD 0.57 billion to USD 1.13 billion (2% in 2025), Clostridium Difficile POC USD 0.43 billion to USD 0.85 billion (1.51% in 2025), HPV POC USD 0.43 billion to USD 1.42 billion (1.51% in 2025), MRSA POC USD 0.43 billion to USD 0.85 billion (1.51% in 2025), Feces USD 0.43 billion to USD 0.85 billion (1.51% in 2025), HSV POC USD 0.29 billion to USD 0.57 billion (1.02% in 2025). Glucose Testing Held the Dominant Share of the Product Segment in 2025 Glucose testing leads because diabetes management already relies on frequent, patient-administered monitoring supported by established reimbursement pathways and long-standing physician familiarity. HPV point-of-care testing is growing fastest as cervical screening guidelines shift toward self-collection and primary HPV testing, drawing volume away from cytology-based pathways and expanding access in settings that previously lacked routine screening infrastructure. The order does not change: Glucose Testing is still largest in 2034, and what moves is how much it holds.
By End-use · 9 segments
By End-use
- Largest Hospitals · 28%
- Fastest Home · 10.4%
- Moves most Home · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $7.98B | 28% | $14.18B | 25%-3 | 6.6% |
| Home | $6.27B | 22% | $15.32B | 27%+5 | 10.4% |
| Physician Office | $3.99B | 14% | $7.38B | 13%-1 | 7.1% |
| Clinics | $2.85B | 10% | $5.11B | 9%-1 | 6.7% |
| Laboratory | $2.85B | 10% | $5.11B | 9%-1 | 6.7% |
| Pharmacy & Retail Clinics | $1.71B | 6% | $3.69B | 6.5%+0.5 | 8.9% |
| Urgent Care Clinics | $1.42B | 5% | $3.12B | 5.5%+0.5 | 9.1% |
| Non-practice Clinics | $0.86B | 3% | $1.70B | 3% | 7.9% |
| Assisted Living Healthcare Facilities | $0.57B | 2% | $1.13B | 2% | 7.9% |
2025 to 2034 revenue and share by line: Hospitals USD 7.98 billion to USD 14.18 billion (28% in 2025), Home USD 6.27 billion to USD 15.32 billion (22% in 2025), Physician Office USD 3.99 billion to USD 7.38 billion (14% in 2025), Clinics USD 2.85 billion to USD 5.11 billion (10% in 2025), Laboratory USD 2.85 billion to USD 5.11 billion (10% in 2025), Pharmacy & Retail Clinics USD 1.71 billion to USD 3.69 billion (6% in 2025), Urgent Care Clinics USD 1.42 billion to USD 3.12 billion (4.98% in 2025), Non-practice Clinics USD 0.86 billion to USD 1.7 billion (3.02% in 2025), Assisted Living Healthcare Facilities USD 0.57 billion to USD 1.13 billion (2% in 2025). Home Outpaces the Axis While Hospitals Holds the Largest Share Hospitals lead because they concentrate acute and emergency testing volume and already operate the quality systems needed to run point-of-care assays alongside central laboratory confirmation. Home testing is growing fastest as chronic disease monitoring and infectious disease screening shift toward patients themselves, supported by simpler device interfaces and telehealth programs that connect a home result to a clinician. By 2034 the largest line is Home and no longer Hospitals, the one axis here where the order actually changes.
By Sample Type · 5 segments
Saliva Outpaces the Axis While Blood/Serum/Plasma Holds the Largest Share
- Largest Blood/Serum/Plasma · 52%
- Fastest Saliva · 12.9%
- Moves most Blood/Serum/Plasma · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood/Serum/Plasma | $14.82B | 52% | $27.24B | 48%-4 | 7% |
| Urine | $5.13B | 18% | $9.65B | 17%-1 | 7.3% |
| Nasal/Nasopharyngeal Swab | $4.27B | 15% | $7.38B | 13%-2 | 6.3% |
| Saliva | $2.28B | 8% | $6.81B | 12%+4 | 12.9% |
| Other | $2B | 7% | $5.66B | 10%+3 | 12.3% |
Blood, serum and plasma sampling leads because it underlies the chronic disease and broad infectious disease panels that make up most point-of-care testing volume, and clinicians trust it for confirmatory accuracy. Saliva-based testing is growing fastest as non-invasive collection gains acceptance for infectious disease and hormonal screening, particularly in pediatric, home and community settings that favor an easier specimen to collect. Blood/Serum/Plasma remains the largest line through 2034, so the axis changes in proportion, not in order.
By Distribution Channel · 3 segments
Direct/Institutional Tender Led by Distribution channel in 2025, with Online/Direct-to-Consumer Growing Fastest
- Largest Direct/Institutional Tender · 62%
- Fastest Online/Direct-to-Consumer · 15.2%
- Moves most Online/Direct-to-Consumer · +8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct/Institutional Tender | $17.67B | 62% | $31.21B | 55%-7 | 6.5% |
| Retail Pharmacy | $7.98B | 28% | $15.32B | 27%-1 | 7.5% |
| Online/Direct-to-Consumer | $2.85B | 10% | $10.21B | 18%+8 | 15.2% |
Institutional and tender-based procurement leads because hospitals, laboratories and public health programs buy point-of-care instruments and consumables under multi-year contracts that favor established suppliers. Online and direct-to-consumer channels are growing fastest as consumers order self-testing kits directly, a route that barely existed for this category before home glucose, fertility and infectious disease tests normalized buying a diagnostic test the way any other health product is bought. Direct/Institutional Tender remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 1 of 5
- 2025 share 38%
- By 2034 34%
- Revenue $10.83B → $19.29B
USD 10.83 billion of 2025 revenue is generated in North America, 38% of the global point of care diagnostic market and reaches USD 19.29 billion by 2034. It is a dominant region on this axis, first by revenue throughout the period.
Share settles at 34% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the technology split tracks the global one; 34% of 2025 revenue in Lateral Flow Assays, fastest growth of 11.62% in Molecular/PCR-based POC. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 85% of it, growing 1.8×.
- In region 1 of 2
- Of region 85%
- Of global 32.3%
- Revenue $9.21B → $16.40B
The United States is the largest market within North America, generating USD 9.21 billion in 2025 and projected to reach USD 16.4 billion by 2034. Carrying 85% of the region in the base year, it sets North America's direction instead of merely contributing to it. Set against USD 10.83 billion and USD 19.29 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The technology pattern in the United States is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Since 85% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by technology for the United States is reported separately in the full report.
Point of care diagnostic devices sold in the United States fall under the Food and Drug Administration's medical device framework, specifically as in vitro diagnostics regulated through the Center for Devices and Radiological Health. Most point of care assays are classified based on the risk they pose to patient safety and the complexity of the testing involved, which determines whether a submission requires premarket notification, premarket approval, or qualifies for a lower-tier exemption. Devices used outside a traditional laboratory setting are also evaluated for waived-testing status under the Clinical Laboratory Improvement Amendments, a separate but connected framework governing where and by whom a test may be run. Manufacturers must maintain quality system compliance, accurate labelling describing intended use and limitations, and clearance documentation before commercial distribution begins.
Competition in the United States runs between the suppliers this study tracks: F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. Volume sits in Lateral Flow Assays at 34% of 2025 revenue; movement sits in Molecular/PCR-based POC at 11.62% growth. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.8×.
- In region 2 of 2
- Of region 15%
- Of global 5.7%
- Revenue $1.62B → $2.89B
Within North America, Canada accounts for 15% of regional revenue and 5.68% of the global total, worth USD 1.62 billion in 2025 and USD 2.89 billion by 2034.
Europe Market Analysis
The 3rd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 22%
- Revenue $6.84B → $12.48B
In Europe, 24% of global revenue puts 2025 at USD 6.84 billion with USD 12.48 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
By 2034 the share stands at 22%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Lateral Flow Assays leads here as it does globally, at 34% of 2025 revenue, and Molecular/PCR-based POC again grows fastest at 11.62%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 27%
- Of global 6.5%
- Revenue $1.85B → $3.37B
The largest single market in Europe is Germany, at USD 1.85 billion in 2025 and USD 3.37 billion in 2034. At 27% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 6.84 billion to USD 12.48 billion over the same period, and this is the market carrying the country-level detail in the full report.
The technology pattern in Germany is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Its 27% weight in Europe means those movements carry straight into the regional totals. Germany carries its own technology breakdown in the full report.
In Germany, point of care diagnostic products are governed by the EU In Vitro Diagnostic Regulation, enforced domestically through the Federal Institute for Drugs and Medical Devices alongside notified bodies authorised to assess conformity. The regulation introduced a risk-based classification system that places most point of care tests under scrutiny proportional to the clinical consequence of an incorrect result, with higher-risk categories requiring notified body involvement rather than manufacturer self-certification alone. Suppliers must demonstrate conformity with applicable harmonised standards, compile technical documentation supporting analytical and clinical performance, and affix the CE marking before a device reaches the German market. Post-market surveillance obligations, including vigilance reporting, continue once the product is in circulation, and labelling must clearly state intended use, storage conditions, and any operator restrictions.
The suppliers tracked in this study (F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.) compete in Germany across the technology lines above. Lateral Flow Assays, at 34% of 2025 revenue, is where the volume sits, and Molecular/PCR-based POC, growing at 11.62%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 6.84 billion in 2025 reaching USD 12.48 billion by 2034, 24% of global revenue at the start of that period.
United Kingdom
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 22%
- Of global 5.3%
- Revenue $1.50B → $2.75B
5.26% of global revenue is generated in the United Kingdom; USD 1.5 billion in 2025, reaching USD 2.75 billion in 2034, and 22% of Europe.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 18%
- Of global 4.3%
- Revenue $1.23B → $2.25B
France is sized at USD 1.23 billion in 2025, rising to USD 2.25 billion by 2034; 4.32% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 6 points of share by 2034, while revenue still grows 2.5×.
- Rank 2 of 5
- 2025 share 26%
- By 2034 32%
- Revenue $7.41B → $18.17B
USD 7.41 billion of 2025 revenue is generated in Asia Pacific, 26% of the global point of care diagnostic market and reaches USD 18.17 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 32% over the forecast period, so the region grows faster than the market's 8.21% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Segment composition follows the global pattern: Lateral Flow Assays largest at 34% of 2025 revenue, Molecular/PCR-based POC fastest at 11.62%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.5×.
- In region 1 of 3
- Of region 34%
- Of global 8.8%
- Revenue $2.52B → $6.18B
China is the largest market within Asia Pacific, generating USD 2.52 billion in 2025 and projected to reach USD 6.18 billion by 2034. 34% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 7.41 billion to USD 18.17 billion over the same period, and this is the market carrying the country-level detail in the full report.
China buys along the same lines as the market globally; Lateral Flow Assays first at 34% of 2025 revenue and 28% in 2034, Molecular/PCR-based POC fastest at 11.62% on a share moving from 15% to 20%. With 34% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by technology for China is reported separately in the full report.
Point of care diagnostic products entering China are regulated by the National Medical Products Administration, which classifies in vitro diagnostic devices according to the risk they present to users and patients. Lower-risk tests may proceed through a registration pathway administered at the provincial level, while higher-risk categories require review and approval directly by the national authority, often supported by clinical evaluation data generated within the country. Imported devices typically need a local agent responsible for regulatory liaison and post-market obligations, and manufacturers must ensure Chinese-language labelling that accurately reflects intended use and handling requirements. Conformity with recognised national standards for manufacturing quality and product performance is also expected, and registration must be renewed periodically to remain valid for continued sale.
The suppliers tracked in this study (F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.) compete in China across the technology lines above. Two different problems sit on the same axis: holding Lateral Flow Assays at 34% of 2025 revenue, and taking Molecular/PCR-based POC while it grows at 11.62%. The commercial size of that position is USD 7.41 billion in 2025, moving to USD 18.17 billion by 2034 across the forecast period.
Japan
2nd-largest in Asia Pacific, growing 2.5×.
- In region 2 of 3
- Of region 22%
- Of global 5.7%
- Revenue $1.63B → $4B
Within Asia Pacific, Japan accounts for 22% of regional revenue and 5.72% of the global total, worth USD 1.63 billion in 2025 and USD 4 billion by 2034.
India
3rd-largest in Asia Pacific, growing 2.4×.
- In region 3 of 3
- Of region 16%
- Of global 4.2%
- Revenue $1.19B → $2.91B
India is sized at USD 1.19 billion in 2025, rising to USD 2.91 billion by 2034; 4.18% of global revenue and 16% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 4 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $1.71B → $3.40B
USD 1.71 billion of 2025 revenue is generated in Latin America, 6% of the global point of care diagnostic market and reaches USD 3.4 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
Share settles at 6% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The technology mix reported at global level applies here, with Lateral Flow Assays the largest line at 34% of 2025 revenue and Molecular/PCR-based POC the fastest-growing at 11.62%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 45%
- Of global 2.7%
- Revenue $0.77B → $1.53B
The largest single market in Latin America is Brazil, at USD 0.77 billion in 2025 and USD 1.53 billion in 2034. Its 45% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 1.71 billion in 2025 and USD 3.4 billion in 2034, it is the country the full report breaks out in detail.
The technology pattern in Brazil is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Since 45% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own technology breakdown in the full report.
Point of care diagnostic devices sold in Brazil are regulated by the National Health Surveillance Agency, known locally as Anvisa, which oversees the registration of in vitro diagnostic products before they may be marketed. The agency applies a risk-based classification approach that determines the depth of technical review a product undergoes, with tests intended for use outside conventional laboratory settings assessed for both analytical reliability and the practical conditions under which non-specialist operators would use them. Manufacturers or their Brazilian representatives must submit technical dossiers demonstrating safety and performance, comply with good manufacturing practice requirements, and provide labelling in Portuguese that clearly states intended use and any operational limitations. Registration must remain current, and products are subject to ongoing post-market monitoring once authorised for sale.
In Brazil the field is F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. The commercially relevant division is 34% of 2025 revenue in Lateral Flow Assays, where the volume is, against 11.62% growth in Molecular/PCR-based POC, where share moves. The commercial size of that position is USD 1.71 billion in 2025, moving to USD 3.4 billion by 2034 across the forecast period.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 30%
- Of global 1.8%
- Revenue $0.51B → $1.02B
Mexico is sized at USD 0.51 billion in 2025, rising to USD 1.02 billion by 2034; 1.79% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $1.71B → $3.40B
6% of the global point of care diagnostic market sits in Middle East and Africa in 2025, worth USD 1.71 billion on the way to USD 3.4 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
Share settles at 6% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Segment composition follows the global pattern: Lateral Flow Assays largest at 34% of 2025 revenue, Molecular/PCR-based POC fastest at 11.62%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.0×.
- In region 1 of 2
- Of region 30%
- Of global 1.8%
- Revenue $0.51B → $1.02B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.51 billion in 2025 and USD 1.02 billion in 2034. 30% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 1.71 billion to USD 3.4 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Lateral Flow Assays at 34% of 2025 revenue, easing to 28% by 2034, and the fastest is Molecular/PCR-based POC at 11.62%, from 15% to 20%. Because the country carries 30% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by technology for Saudi Arabia is reported separately in the full report.
In Saudi Arabia, point of care diagnostic devices fall under the authority of the Saudi Food and Drug Authority, which maintains a medical device registration system aligned in structure with international regulatory practice. Products are classified according to risk, and manufacturers or their authorised local representatives must submit registration applications supported by evidence of conformity assessment, often referencing approvals already granted by a recognised foreign regulator as part of the review. Establishment licensing is required for the local entity responsible for importing and distributing the device, and labelling must be provided in Arabic alongside the original language, stating intended use and handling instructions clearly. Ongoing compliance includes adverse event reporting and maintaining registration validity for as long as the product remains on the market.
In Saudi Arabia the field is F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. The commercially relevant division is 34% of 2025 revenue in Lateral Flow Assays, where the volume is, against 11.62% growth in Molecular/PCR-based POC, where share moves. The commercial size of that position is USD 1.71 billion in 2025 and USD 3.4 billion by 2034, 6% of the global total in the base year.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 22%
- Of global 1.3%
- Revenue $0.38B → $0.75B
1.33% of global revenue is generated in South Africa; USD 0.38 billion in 2025, reaching USD 0.75 billion in 2034, and 22% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by technology, product, end-use, sample type, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Lateral Flow Assays Volume and Molecular/PCR-based POC Momentum
The field covered here is F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc..
Competition follows the technology split, not the regional one. Volume sits in Lateral Flow Assays, USD 9.69 billion and 34% of 2025 revenue, 28% by 2034, which is also where an incumbent is hardest to dislodge. Share moves in Molecular/PCR-based POC, growing 11.62% against 5.88% for Lateral Flow Assays. Those are different problems, and a supplier strong in one is not thereby strong in the other; that is what sustains a field this size in a USD 28.5 billion market.
Suppliers compete on regulatory and clearance experience across the many analyte categories this market spans, since a single company rarely holds clearances across glucose, infectious disease and coagulation testing without years of submissions behind it. Manufacturing scale and consumable-cartridge reliability matter as much as the reader instrument itself, because a stockout of test strips or cartridges is what a buyer actually notices. Distribution reach into hospital, retail pharmacy and home channels separates the largest suppliers from regional specialists, who instead compete on price and service responsiveness within a single analyte category or geography.
Presence matters unevenly by region. With 38% of 2025 revenue in North America and 26% in Asia Pacific, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Point Of Care Diagnostic Market Companies Profiled
17 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- F. Hoffmann-La Roche Ltd.(Switzerland)
- Danaher(United States)
- BD(United States)
- Qiagen(Netherlands)
- Abbott(United States)
- Siemens Healthcare AG(Germany)
- bioMerieux SA(France)
- Zoetis, Inc.(United States)
- Instrumentation Laboratory(United States)
- Nova Biomedical(United States)
- Quidel Corp.(United States)
- Trividia Health, Inc.(United States)
- Sekisui Diagnostics(United States)
- Nipro Corp.(Japan)
- Trinity Biotech(Ireland)
- Orasure Technologies, Inc.(United States)
- Spectral Medical, Inc.(Canada)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Technology, Product, End-use, Sample Type, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 17 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Point Of Care Diagnostic Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Point Of Care Diagnostic Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Point Of Care Diagnostic Market Overview, By Product, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Point Of Care Diagnostic Market Overview, By End-use, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Point Of Care Diagnostic Market Overview, By Sample Type, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Point Of Care Diagnostic Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Point Of Care Diagnostic Market Size — Segment Comparison
Chapter 22.Global Point Of Care Diagnostic Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Point Of Care Diagnostic Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Point Of Care Diagnostic Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Point Of Care Diagnostic Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Point Of Care Diagnostic Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Point Of Care Diagnostic Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Technology
5- 01Lateral Flow Assays
- 02Immunoassay-based Platforms
- 03Biosensor-based Platforms
- 04Molecular/PCR-based POC
- 05Microfluidics-based Platforms
By Product
27- 01Glucose Testing
- 02Hb1Ac Testing
- 03Coagulation Testing
- 04Fertility/Pregnancy
- 05Infectious Disease
- 06HIV POC
- 07Clostridium Difficile POC
- 08HBV POC
- 09Pneumonia or Streptococcus Associated Infections
- 10HPV POC
- 11Influenza/Flu POC
- 12HCV POC
- 13MRSA POC
- 14TB and Drug-resistant TB POC
- 15HSV POC
- 16COVID-19
- 17Other Infectious Diseases
- 18Thyroid Stimulating Hormone
- 19Hematology
- 20Primary Care Systems
- 21Feces
- 22Lipid Testing
- 23Cancer Marker
- 24Blood Gas/Electrolytes
- 25Ambulatory Chemistry
- 26Drug of Abuse (DOA) Testing
- 27Urinalysis/Nephrology
By End-use
9- 01Hospitals
- 02Home
- 03Physician Office
- 04Clinics
- 05Laboratory
- 06Pharmacy & Retail Clinics
- 07Urgent Care Clinics
- 08Non-practice Clinics
- 09Assisted Living Healthcare Facilities
By Sample Type
5- 01Blood/Serum/Plasma
- 02Urine
- 03Nasal/Nasopharyngeal Swab
- 04Saliva
- 05Other
By Distribution Channel
3- 01Direct/Institutional Tender
- 02Retail Pharmacy
- 03Online/Direct-to-Consumer
Segment categories shown for scope reference. See the Summary tab for revenue share by By Technology. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The size was built upward from unit volumes and realized prices across the market's major testing categories: glucose meters and strips, infectious disease cartridges and lateral flow strips, coagulation and blood gas analyzers, and their associated consumables. Reported device placements, strip and cartridge shipment volumes, and average selling prices by channel were combined to build category-level revenue, then aggregated to the market total. That bottom-up build was checked against disclosed revenue from the diagnostics segments of the major listed suppliers named in this report; where a category's bottom-up total implied a share of a company's disclosed diagnostics revenue that looked implausibly high or low, the underlying volume or price assumption for that category was revisited and corrected rather than averaging the two figures together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target commercial and product-line managers at instrument and consumable manufacturers, hospital and reference laboratory procurement leads, retail pharmacy category buyers, and regulatory affairs staff who manage clearance submissions for point-of-care assays. These roles were chosen because they hold the pricing, channel-mix and approval-timing information that a published filing does not disclose at the category level. Sampling emphasises North America and Europe, where clearance pathways are best documented and procurement contacts are most reachable, supplemented by Asia Pacific contacts covering China, Japan and India given the region's share of testing volume and its faster adoption of newer platforms.
Desk research draws on FDA 510(k) and CLIA waiver clearance listings, which identify which specific point-of-care assays are authorized in the United States and by which manufacturer; EU IVDR notified body registers for the equivalent European clearances; World Health Organization prequalification listings for infectious disease rapid tests used in public health procurement; and published tender and procurement records from national health services and multilateral buyers such as the Global Fund. Trade association benchmarks from bodies including AdvaMed supplement these registers with category-level shipment and adoption context not captured in any single regulatory database.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the pace at which chronic disease monitoring and infectious disease screening continue shifting from central laboratories to the point of care, the rate at which newer molecular and biosensor platforms gain clearance and reimbursement, and the pricing behavior of high-volume consumables as competition increases. It normalizes for the COVID-19 testing surge recorded in 2020 and 2021 and the subsequent decline through 2023, treating that period as an anomaly rather than a trend line to extend. For the forecast to hold, decentralization of testing must continue at a comparable pace to the last five years and no comparable one-time demand shock should recur.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against each category's recorded historical growth from 2020 through 2024, including the post-pandemic decline in infectious disease testing volume, to confirm the model reproduces a pattern already observed rather than only a projected one. Segment-level share shifts, particularly the move toward home and molecular testing, were reviewed against the primary interviews described above for directional agreement. Sensitivities were tested around reimbursement policy changes for point-of-care testing and around the pace of clearance approvals for newer platforms, since both are the assumptions most likely to move the forecast if they change faster or slower than modeled.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is highest in glucose testing and hospital-based use, where device placement and reimbursement data are well documented and stable over time. It is lower in home testing and in newer molecular and biosensor categories, where adoption is still forming and consumer purchase data is thinner than institutional procurement data. A structural risk to this estimate is a sudden reimbursement policy change in a major market, which would shift testing volume between settings faster than the historical pattern this forecast is built from. This report's confidence level is stated as medium rather than high given that gap.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Point Of Care Diagnostic Market projected to reach?
USD 56.74 Billion by 2034, CAGR 8.21%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 38% of global revenue through 2034.
05Which segment leads the market?
Lateral Flow Assays is the largest line by technology, at 34% of revenue in 2025.
06Who are the key companies profiled?
F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc., Spectral Medical, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.